The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Jean-Noël,Hubert

第一单位： Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 69372 Lyon, France.

作者： Jean-Noël,Hubert ^[1] ; Voreak,Suybeng ^[2] ; Maxime,Vallée ^[1] ; Tiffany M,Delhomme ^[1] ; Eve,Maubec ^[3] ; Anne,Boland ^[4] ; Delphine,Bacq ^[5] ; Jean-François,Deleuze ^[5] ; Fanélie,Jouenne ^[5] ; Paul,Brennan ^[2] ; James D,McKay ^[1] ; Marie-Françoise,Avril ^[1] ; Brigitte,Bressac-de Paillerets ^[6] ; Estelle,Chanudet ^[2]

作者单位： Section of Genetics, International Agency for Research on Cancer (IARC-WHO), 69372 Lyon, France. ^[1] Gustave Roussy, Département de Biopathologie, 94805 Villejuif, France. ^[2] Department of Dermatology, AP-HP, Hôpital Avicenne, University Paris 13, 93000 Bobigny, France. ^[3] UMRS-1124, Campus Paris Saint-Germain-des-Prés, University of Paris, 75006 Paris, France. ^[4] Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, CEA, 91057 Evry, France. ^[5] Association Robert Debré pour la Recherche Médicale, 75006 Paris, France. ^[6] INSERM U1279, Tumor Cell Dynamics, 94805 Villejuif, France. ^[7]

关键词 WES genetic susceptibility melanoma rare variants enrichment renal cell carcinoma

DOI 10.3390/cancers13092243

PMID 34067022

发布时间 2024-03-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交